Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow
Best PFS In Second Line Setting
Executive Summary
The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.
You may also be interested in...
Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves
KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.
Sanofi Challenges J&J’s Darzalex With Blackstone Pact For SC Sarclisa
The French major has entered a risk-sharing collaboration with Blackstone focused on a new formulation of multiple myeloma drug Sarclisa, which could help it take on market leader Darzalex.
Sanofi Makes Case For Frontline Use Of Myeloma Drug Sarclisa
Sarclisa, Sanofi's first in-house cancer drug to be approved since 2010, is making slow if steady progress on the sales front but remains way behind J&J's multiple myeloma behemoth Darzalex. Still, the company has been touting its case to be the anti-CD38 of choice at the ASH meeting.